Aluminum and Intravenous Drugs in the Neonate
Aluminum and Intravenous Drugs in the Neonate
复制标题
新生儿的铝和静脉药物
DOI：
10.1177/106002809302701222
复制
发表时间：
1993
期刊：
影响因子：
--
通讯作者：
Á. Ballabriga
中科院分区：
文献类型：
--
作者：
A. Moreno;C. Domínguez;C. Barroso;Á. Ballabriga
致编辑：富兰的铝（AI）组织存款生产。研究表明AI可能是早产儿骨质减少和某些原因不明的脑病的病因之一。肠外营养（PN）溶液，主要是钙盐污染，其次是白蛋白，似乎是最广泛描述的来源。对于大容量和重复的肠外溶液，食品和药物管理局已考虑将上限设定为0.93 μ mol/L。
TO THE EDITOR: Aluminum (AI) tissue deposit production in fulland. pretenn newborns receiving intravenous (iv) solutions has been described.P It has been suggested that AI could be one of the causal factors of premature osteopenia' and some cases of unexplained encephalopathy.' Parenteral nutrition (PN) solutions, mainly by calcium salts contamination and, to a lesser degree, albumin, appear to be the most widely described sources.P For large-volume and repeated parenteral solutions, the Food and Drug Administration has considered setting an upper limit ofO.93IlmoVAI/L.4